CYP46A1 and Dravet syndrome: Soticlestat (TAK-935/OV935) is the first potent, selective, and CNS-penetrant inhibitor of cholesterol 24-hydroxylase (CH24H) being investigated as an adjunctive treatment for seizures associated with DEEs, including DS and LGS (Nishi et al., 2022).